Latest news and upcoming events

26 May 2021

Ysios Capital closes its third fund at €216 million ($260 million)

Upcoming events
  • Biospain 2021
    29 September – 1 October 2021,
    Pamplona, Spain

  • Biotech Europe Forum 2021
    7 October – 8 October 2021,

  • Venture Capital Forum 2021
    13 October – 14 October 2021,

Aura Biosciences Assembles New Bladder Cancer Focused Scientific Advisory Board

The new SAB will be comprised of seven members and will work closely with Aura’s senior management.

AM-Pharma Appoints Martijn Negen as VP Commercial Strategy

Martijn Negen has over 20 years of experience in pharmaceutical, biotech and diagnostic companies.

VarmX appoints Dr. Jan Öhrström as CEO, and Dr. Alex Gold to Supervisory Board

VarmX today announces the appointment of Dr. Gerard Short, MBBS, as Chief Medical Officer (CMO).

CorWave Successfully Performed a 90-Day In Vivo Study on Its Revolutionary Cardiac Pump Synchronized With the Native Heart, Results Presented at ASAIO Meeting

These data confirmed the ability of the CorWave pump to provide chronic circulatory support with exceptional hemocompatibility.

OxThera reports results from Phase 3 ePHex study with Oxabact in primary hyperoxaluria patients with maintained kidney function

OxThera AB, announces completion of its pivotal Phase 3 study and reports top line results.

Aura Biosciences Appoints Sapna Srivastava, Ph.D., to its Board of Directors

Dr. Srivastava is currently the Chief Financial and Strategy Officer at eGenesis.

Minoryx publishes mechanism of action of leriglitazone in X-ALD in Science Translational Medicine journal

Published results show efficacy in both adrenomyeloneuropathy (AMN) and cerebral ALD (cALD) related models.

Ysios Capital closes its third fund at €216 million ($260 million)

To invest in up to 15 companies in Europe and the US, with eight investments already made alongside top US and European investors.

AELIX Therapeutics appoints Dr Melanie Rolli as CEO

Dr Rolli will support the company’s vision of positioning HTI vaccines for future functional cure strategies.

SparingVision to Present at the American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting

SparingVision has presented three posters highlighting the Company’s recent research into ocular diseases and its lead gene therapy treatment, SPVN06.


Subscribe to our weekly newsletter for the latest
updates on life sciences investments.